Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: A 12-month, open-label, flexible-dose study with an extension period

Journal of Clinical Sleep Medicine

Volumn 6, Issue 5, 2010, Pages 450-457

  Schwartz, Jonathan R L ^a   Khan, Arifulla ^b   McCall, W Vaughn ^c   Weintraub, James ^d   Tiller, Jane ^e  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Northwest Clinical Research Center   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Michigan Head Pain and Neurological Institute   (United States)

^e CEPHALON INC   (United States)

Author keywords

Armodafinil; Excessive sleepiness; Narcolepsy; Obstructive sleep apnea; Shift work disorder; Wakefulness

Indexed keywords

ANTICATAPLECTIC AGENT; ARMODAFINIL; CENTRAL STIMULANT AGENT; CONTRACEPTIVE AGENT; MODAFINIL; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATED DEPRESSION; ANXIETY DISORDER; ARTICLE; BRONCHITIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; FEMALE; HEART INFARCTION; HUMAN; HYPERSOMNIA; HYPERTENSION; INSOMNIA; IRRITABILITY; LONG QT SYNDROME; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; NIGHT; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; RHINOPHARYNGITIS; SCORING SYSTEM; SHIFT WORK DISORDER; SIDE EFFECT; SINUSITIS; SLEEP APNEA SYNDROME; SLEEP DISORDER; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WAKEFULNESS; WORK;

EID: 78149324914     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27934     Document Type: Article

References (37)

1. Baldwin CM, Vishesh KK, Holberg CJ, et al. Associations between gender and measures of daytime somnolence in the Sleep Heart Health Study. Sleep 2004;27:305-11.
2. Mignot E, Lin L, Finn L, et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006;129:1609-23.
3. Singh M, Drake CL, Roth T. The prevalence of multiple-sleep-onset REM periods in a population-based sample. Sleep 2006;29:890-5.
4. Leger D. The cost of sleep-related accidents: a report for the national commission on sleep disorders research. Sleep 1994;17:84-93.
5. Mitler M, Carskadon M, Czeisler C, et al. Catastrophes, sleep, and public policy: consensus report. Sleep 1988;11:100-9.
6. Dinges DF. An overview of sleepiness and accidents. J Sleep Res 1995;4:4-14.
7. Lindberg E, Carter N, Gislason T, et al. Role of snoring and daytime sleepiness in occupational accidents. Am J Respir Crit Care Med 2001;164:2031-5.
8. Powell NB, Schectman KB, Riley RW, et al. The road to danger: the comparative risks of driving while sleepy. Laryngoscope 2001;111:887-93.
9. MacLean AW, Davies DRT, Thiele K. The hazards and prevention of driving while sleepy. Sleep Med Reviews 2003;7:507-21.
10. Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004,27:1453-62.
11. Gander PH, Marshall NS, Harris RB, et al. Sleep, sleepiness and motor vehicle accidents: a national survey. Aust N Z J Public Health 2005;29:16-21.
12. Powell NB, Schectman KB, Riley RW, et al. Sleepy driver near-misses may predict accident risks. Sleep 2007;30:331-42.
13. American Academy of Sleep Medicine. International classification of sleep disorders: diagnostic and coding manual. 2nd edition. Westchester: American Academy of Sleep Medicine, 2005.
14. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007;30:711-9.
15. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39:281-8.
16. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39:30-40.
17. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-37.
18. Darwish M, Kirby M, Hellriegel ET, Yang R, Robertson P Jr. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from 3 randomized studies. Clin Drug Investig 2009;29:87-100.
19. NUVIGIL [package insert]. Frazer, PA: Cephalon, Inc.; 2007.
20. Drake C, Walsh J, Roth T. Armodafinil improves sleep latency in patients with shift work disorder. Sleep 2006;29:A64.
21. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74.
22. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006;28:689-706.
23. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007;101:616-27.
24. United States Department of Health and Human Services. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Rockville, MD: United States Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, April 1996. Available at: http://www.fda.gov/cder/guidance/959fnl.pdf.
25. American Sleep Disorders Association. International classification of sleep disorders: diagnostic and coding manual. Rochester: American Sleep Disorders Association, 2000.
26. Guy W. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, 1976.
27. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
28. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376-81.
29. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.
30. Nieto FJ, Young TB, Lind BK, et al. Association of sleep disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000;283:1829-36.
31. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50:S16-22.
32. Engleman HM, Martin SE, Douglas NJ. Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax 1994;49:263-6.
33. Reeves-Hoche MK, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994;149:149-54.
34. Krieger J, Kurtz D, Petiau C, et al. Long-term compliance with CPAP therapy in obstructive sleep apnea patients and in snorers. Sleep 1996;19:S136-43.
35. Pieters T, Collard P, Aubert G, et al. Acceptance and long-term compliance with nCPAP in patients with obstructive sleep apnoea syndrome. Eur Respir J 1996;9:939-44.
36. Collard P, Pieters T, Aubert G, et al. Compliance with nasal CPAP in obstructive sleep apnea patients. Sleep Med Rev 1997;1:33-44.
37. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.